Switch to:
Also traded in: Germany, India, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.35
NYSE:RDY's Cash to Debt is ranked lower than
73% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. NYSE:RDY: 0.35 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:RDY' s Cash to Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.73 Max: No Debt
Current: 0.35
Equity to Asset 0.52
NYSE:RDY's Equity to Asset is ranked lower than
67% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NYSE:RDY: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:RDY' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.56 Max: 0.82
Current: 0.52
0.31
0.82
Interest Coverage 104.66
NYSE:RDY's Interest Coverage is ranked higher than
50% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.15 vs. NYSE:RDY: 104.66 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:RDY' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 20.43 Max: 104.75
Current: 104.66
3.11
104.75
F-Score: 5
Z-Score: 4.68
M-Score: -1.98
WACC vs ROIC
2.60%
27.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 43.50
NYSE:RDY's Operating margin (%) is ranked higher than
97% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. NYSE:RDY: 43.50 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:RDY' s Operating margin (%) Range Over the Past 10 Years
Min: -4.08  Med: 17.49 Max: 43.5
Current: 43.5
-4.08
43.5
Net-margin (%) 8.26
NYSE:RDY's Net-margin (%) is ranked higher than
59% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NYSE:RDY: 8.26 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:RDY' s Net-margin (%) Range Over the Past 10 Years
Min: -7.44  Med: 14.38 Max: 16.28
Current: 8.26
-7.44
16.28
ROE (%) 9.88
NYSE:RDY's ROE (%) is ranked higher than
62% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. NYSE:RDY: 9.88 )
Ranked among companies with meaningful ROE (%) only.
NYSE:RDY' s ROE (%) Range Over the Past 10 Years
Min: -11.6  Med: 23.4 Max: 29.21
Current: 9.88
-11.6
29.21
ROA (%) 5.81
NYSE:RDY's ROA (%) is ranked higher than
63% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NYSE:RDY: 5.81 )
Ranked among companies with meaningful ROA (%) only.
NYSE:RDY' s ROA (%) Range Over the Past 10 Years
Min: -6.11  Med: 12.11 Max: 13.77
Current: 5.81
-6.11
13.77
ROC (Joel Greenblatt) (%) 19.25
NYSE:RDY's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. NYSE:RDY: 19.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:RDY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7.36  Med: 32.37 Max: 65.25
Current: 19.25
-7.36
65.25
Revenue Growth (3Y)(%) 9.90
NYSE:RDY's Revenue Growth (3Y)(%) is ranked higher than
63% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NYSE:RDY: 9.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:RDY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.4  Med: 15 Max: 46.1
Current: 9.9
0.4
46.1
EBITDA Growth (3Y)(%) 11.80
NYSE:RDY's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. NYSE:RDY: 11.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:RDY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37  Med: 14.5 Max: 154.4
Current: 11.8
-37
154.4
EPS Growth (3Y)(%) 8.20
NYSE:RDY's EPS Growth (3Y)(%) is ranked higher than
52% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NYSE:RDY: 8.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:RDY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65  Med: 24.7 Max: 154.7
Current: 8.2
-65
154.7
» NYSE:RDY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

RDY Guru Trades in Q4 2015

Jeremy Grantham 7,700 sh (+45.28%)
Ken Fisher 4,504,956 sh (-9.20%)
Sarah Ketterer 374,100 sh (-36.23%)
Jim Simons 70,700 sh (-39.68%)
» More
Q1 2016

RDY Guru Trades in Q1 2016

Jeremy Grantham 86,700 sh (+1025.97%)
Ken Fisher 4,775,345 sh (+6.00%)
Sarah Ketterer 380,200 sh (+1.63%)
Jim Simons 24,300 sh (-65.63%)
» More
Q2 2016

RDY Guru Trades in Q2 2016

Jim Simons 132,300 sh (+444.44%)
Ken Fisher 5,227,024 sh (+9.46%)
Jeremy Grantham 80,200 sh (-7.50%)
Sarah Ketterer 294,600 sh (-22.51%)
» More
Q3 2016

RDY Guru Trades in Q3 2016

Ken Fisher 5,696,909 sh (+8.99%)
Jim Simons Sold Out
Sarah Ketterer 191,543 sh (-34.98%)
Jeremy Grantham 50,200 sh (-37.41%)
» More
» Details

Insider Trades

Latest Guru Trades with RDY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:SFOSF, OTCPK:HLUYY, NYSE:MNK, NAS:OPK, NYSE:VRX, OTCPK:APNHY, OTCPK:IPSEY, OTCPK:HYPMY, OTCPK:ITHUF, OTCPK:HKMPF, OTCPK:MTZPY, NYSE:TARO, NAS:NBIX, NYSE:PTHN, NAS:ENDP, NAS:HZNP, NYSE:CTLT, OTCPK:INVVY, NAS:AKRX, NYSE:PRGO » details
Traded in other countries:RDDA.Germany, 500124.India, RDY N.Mexico,
Dr Reddy Laboratories Ltd together with its subsidiaries is engaged in manufacturing of pharmaceutical products. It operates through three segments; Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.

Dr Reddy's Laboratories Ltd was incorporated in India as a Private Limited Company on February 24, 1984. The Company converted to a Public Limited Company on December 6, 1985. The Company together with its subsidiaries is an India-based pharmaceutical company engaged in manufacturing of pharmaceutical products. The Company operates through three segments; Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. The Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients ("APIs"), Custom Pharmaceutical Services ("CPS"), generics, biosimilars, differentiated formulations and New Chemical Entities ("NCEs"). The Global Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company's biologics business. The Pharmaceutical Services and Active Ingredients segment includes active pharmaceutical ingredients and intermediaries, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediaries become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company's differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes the Company's specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company's products includes; Zoledronic acid, Azacitidine, Moxifloxacin, Decitabine, Donepezil 23 mg, and Sumatriptan Auto Injector. The Company's competitors include Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Alkem Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited. Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Limited, Nycomed International Management GmbH and Zentiva N.V. The Company's manufacturing and marketing of drugs, drug products and cosmetics is governed by many statutes, regulations and gui

Ratios

vs
industry
vs
history
P/E(ttm) 44.09
RDY's P/E(ttm) is ranked lower than
68% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.49 vs. RDY: 44.09 )
Ranked among companies with meaningful P/E(ttm) only.
RDY' s P/E(ttm) Range Over the Past 10 Years
Min: 10.61  Med: 23.43 Max: 361.99
Current: 44.09
10.61
361.99
Forward P/E 23.04
RDY's Forward P/E is ranked lower than
73% of the 63 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. RDY: 23.04 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 44.09
RDY's PE(NRI) is ranked lower than
69% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.46 vs. RDY: 44.09 )
Ranked among companies with meaningful PE(NRI) only.
RDY' s PE(NRI) Range Over the Past 10 Years
Min: 10.61  Med: 23.43 Max: 361.99
Current: 44.09
10.61
361.99
Price/Owner Earnings (ttm) 44.06
RDY's Price/Owner Earnings (ttm) is ranked lower than
63% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.53 vs. RDY: 44.06 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RDY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.37  Med: 50.25 Max: 493.43
Current: 44.06
11.37
493.43
P/B 4.57
RDY's P/B is ranked lower than
72% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. RDY: 4.57 )
Ranked among companies with meaningful P/B only.
RDY' s P/B Range Over the Past 10 Years
Min: 1.27  Med: 4.69 Max: 6.72
Current: 4.57
1.27
6.72
P/S 3.71
RDY's P/S is ranked lower than
59% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. RDY: 3.71 )
Ranked among companies with meaningful P/S only.
RDY' s P/S Range Over the Past 10 Years
Min: 0.94  Med: 3.03 Max: 5.29
Current: 3.71
0.94
5.29
POCF 18.77
RDY's POCF is ranked lower than
55% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.41 vs. RDY: 18.77 )
Ranked among companies with meaningful POCF only.
RDY' s POCF Range Over the Past 10 Years
Min: 6.71  Med: 20.48 Max: 166.18
Current: 18.77
6.71
166.18
EV-to-EBIT 32.27
RDY's EV-to-EBIT is ranked lower than
71% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.07 vs. RDY: 32.27 )
Ranked among companies with meaningful EV-to-EBIT only.
RDY' s EV-to-EBIT Range Over the Past 10 Years
Min: -497.4  Med: 17.7 Max: 276.7
Current: 32.27
-497.4
276.7
EV-to-EBITDA 19.93
RDY's EV-to-EBITDA is ranked lower than
58% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.70 vs. RDY: 19.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
RDY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.5  Med: 13.45 Max: 75.1
Current: 19.93
-43.5
75.1
PEG 2.50
RDY's PEG is ranked lower than
58% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.95 vs. RDY: 2.50 )
Ranked among companies with meaningful PEG only.
RDY' s PEG Range Over the Past 10 Years
Min: 0.24  Med: 0.83 Max: 3.61
Current: 2.5
0.24
3.61
Shiller P/E 45.22
RDY's Shiller P/E is ranked higher than
50% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.94 vs. RDY: 45.22 )
Ranked among companies with meaningful Shiller P/E only.
RDY' s Shiller P/E Range Over the Past 10 Years
Min: 41.02  Med: 59.17 Max: 72.5
Current: 45.22
41.02
72.5
Current Ratio 1.12
RDY's Current Ratio is ranked lower than
83% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. RDY: 1.12 )
Ranked among companies with meaningful Current Ratio only.
RDY' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.83 Max: 5.29
Current: 1.12
1.04
5.29
Quick Ratio 0.80
RDY's Quick Ratio is ranked lower than
82% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. RDY: 0.80 )
Ranked among companies with meaningful Quick Ratio only.
RDY' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.38 Max: 4.3
Current: 0.8
0.68
4.3
Days Inventory 321.39
RDY's Days Inventory is ranked lower than
94% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.28 vs. RDY: 321.39 )
Ranked among companies with meaningful Days Inventory only.
RDY' s Days Inventory Range Over the Past 10 Years
Min: 77.02  Med: 143.49 Max: 321.39
Current: 321.39
77.02
321.39
Days Sales Outstanding 92.56
RDY's Days Sales Outstanding is ranked lower than
62% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. RDY: 92.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.16  Med: 90.62 Max: 124.17
Current: 92.56
42.16
124.17
Days Payable 111.34
RDY's Days Payable is ranked higher than
72% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.88 vs. RDY: 111.34 )
Ranked among companies with meaningful Days Payable only.
RDY' s Days Payable Range Over the Past 10 Years
Min: 50.72  Med: 80.07 Max: 111.34
Current: 111.34
50.72
111.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.65
RDY's Dividend Yield is ranked lower than
82% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. RDY: 0.65 )
Ranked among companies with meaningful Dividend Yield only.
RDY' s Dividend Yield Range Over the Past 10 Years
Min: 0.3  Med: 0.62 Max: 0.97
Current: 0.65
0.3
0.97
Dividend Payout 0.32
RDY's Dividend Payout is ranked higher than
54% of the 386 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. RDY: 0.32 )
Ranked among companies with meaningful Dividend Payout only.
RDY' s Dividend Payout Range Over the Past 10 Years
Min: 0.2  Med: 0.47 Max: 1.13
Current: 0.32
0.2
1.13
Dividend Growth (3y) 13.30
RDY's Dividend Growth (3y) is ranked higher than
60% of the 286 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.00 vs. RDY: 13.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RDY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -10.6  Med: 17 Max: 171.4
Current: 13.3
-10.6
171.4
Forward Dividend Yield 0.64
RDY's Forward Dividend Yield is ranked lower than
83% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. RDY: 0.64 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.21
RDY's Yield on cost (5-Year) is ranked lower than
68% of the 791 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. RDY: 1.21 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RDY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.56  Med: 1.16 Max: 1.81
Current: 1.21
0.56
1.81
3-Year Average Share Buyback Ratio -0.20
RDY's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. RDY: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RDY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.6  Med: -0.2 Max: 0
Current: -0.2
-6.6
0

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.17
RDY's Price/Tangible Book is ranked lower than
80% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. RDY: 8.17 )
Ranked among companies with meaningful Price/Tangible Book only.
RDY' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.07  Med: 6.29 Max: 83.42
Current: 8.17
3.07
83.42
Price/Projected FCF 3.22
RDY's Price/Projected FCF is ranked lower than
54% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. RDY: 3.22 )
Ranked among companies with meaningful Price/Projected FCF only.
RDY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.48  Med: 3.05 Max: 4.67
Current: 3.22
1.48
4.67
Price/DCF (Earnings Based) 4.10
RDY's Price/DCF (Earnings Based) is ranked lower than
94% of the 79 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. RDY: 4.10 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.22
RDY's Price/Median PS Value is ranked lower than
56% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. RDY: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
RDY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.04 Max: 1.84
Current: 1.22
0.39
1.84
Price/Peter Lynch Fair Value 2.42
RDY's Price/Peter Lynch Fair Value is ranked lower than
69% of the 142 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. RDY: 2.42 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
RDY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.55  Med: 1.07 Max: 2.44
Current: 2.42
0.55
2.44
Price/Graham Number 3.99
RDY's Price/Graham Number is ranked lower than
77% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. RDY: 3.99 )
Ranked among companies with meaningful Price/Graham Number only.
RDY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.67  Med: 2.63 Max: 11.05
Current: 3.99
1.67
11.05
Earnings Yield (Greenblatt) (%) 3.09
RDY's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. RDY: 3.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RDY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 5.4 Max: 11.4
Current: 3.09
0.4
11.4
Forward Rate of Return (Yacktman) (%) 19.50
RDY's Forward Rate of Return (Yacktman) (%) is ranked higher than
73% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.15 vs. RDY: 19.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RDY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -9.4  Med: 1.8 Max: 50.4
Current: 19.5
-9.4
50.4

More Statistics

Revenue (TTM) (Mil) $2,177
EPS (TTM) $ 1.09
Beta0.30
Short Percentage of Float3.29%
52-Week Range $40.68 - 54.73
Shares Outstanding (Mil)165.53

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 2,167 2,407
EPS ($) 1.45 2.02
EPS w/o NRI ($) 1.45 2.02
EPS Growth Rate
(3Y to 5Y Estimate)
15.14%
Dividends Per Share ($) 0.00 0.00
» More Articles for NYSE:RDY

Headlines

Articles On GuruFocus.com
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Ken Fisher Sells Shares of PMC Sierra, Alphabet During 4th Quarter Jan 15 2016 
Emerging Market Stocks To Watch Out For Feb 17 2015 
Should You Buy Actavis? Mar 18 2014 
Dr. Reddy’s Laboratories: Should Continue to Gain Market Share in Lucrative Markets May 25 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
Abbott Laboratories and the “India Cure” for the Ailing Pharmaceutical Industry May 26 2010 

More From Other Websites
Dr. Reddy's Laboratories Announces the Launch of Nystatin and Triamcinolone Acetonide Cream, USP in... Dec 05 2016
Dr. Reddy's Laboratories Announces the Launch of Nystatin and Triamcinolone Acetonide Cream, USP in... Dec 05 2016
Arch Capital Group Ltd. (ACGL): Are Hedge Funds Right About This Stock? Dec 02 2016
Is Newfield Exploration Co. (NFX) A Good Stock To Buy Right Now? Dec 01 2016
How One Woman Silenced Her Twitter Trolls With a 78% Stock Rally Nov 30 2016
Is Coty Inc (COTY) a Good Stock To Buy? Nov 29 2016
Will Demonetization in India Impact Your Loan Burden? Nov 23 2016
Dr. Reddy’s Labs Launches New Drug (RDY) Nov 14 2016
Blog Coverage Dr. Reddy's Labs Launches Generic Osteoporosis Drug Tablets in the US Nov 14 2016
Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market Nov 11 2016
Dr. Reddy's Laboratories Announces the Launch of Raloxifene HCl Tablets, USP in the U.S. Market Nov 11 2016
Dr. Reddy's Laboratories Announces the Launch of Raloxifene HCl Tablets, USP in the U.S. Market Nov 11 2016
ETF’s with exposure to Dr. Reddy’s Laboratories Ltd. : October 28, 2016 Oct 28 2016
Dr. Reddy’s Laboratories Ltd. :RDY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 27,... Oct 27 2016
Dr. Reddy's Laboratories Announces New Strategic Deal with Gland Pharma in the U.S. Market Oct 26 2016
Dr. Reddy's Laboratories Announces New Strategic Deal with Gland Pharma in the U.S. Market Oct 26 2016
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2 Oct 26 2016
What Gives? Dr. Reddy's Shares Jump 6% Despite Earnings Miss Oct 25 2016
Doctor Reddy's posts 2Q profit Oct 25 2016
Dr. Reddy’s Q2 and H1 FY17 Financial Results Oct 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)